James Larkin
Impact in
- Oncology top 0.01%
- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- Cancer Cells and Metastasis
- Cancer Research top 0.1%
- Cancer Genomics and Diagnostics
Papers in
- Oncology 268
- Cancer Immunotherapy and Biomarkers 213
- Cutaneous Melanoma Detection and Management 62
- CAR-T cell therapy research 9
-
- Renal cell carcinoma treatment 149
- Brain Metastases and Treatment 10
- Co-authors
- Caroline Robert (41 shared papers)Georgina Venetia Long (38 shared papers)Martin Eric Gore (75 shared papers)Lavinia Anne Spain (27 shared papers)Charles Swanton (22 shared papers)Matteo Salvatore Carlino (14 shared papers)John B.A.G. Haanen (20 shared papers)Solange Peters (4 shared papers)
- Journals
- Annals of Oncology (81 papers)European Journal of Cancer (43 papers)The Lancet Oncology (35 papers)Journal of Clinical Oncology (32 papers)New England Journal of Medicine (20 papers)
- Partner nations
- United KingdomUnited StatesFrance
In The Last Decade
James Larkin
538 papers receiving 97.2k citations
James Larkin's Hit Papers
Peers
Comparison fields: 5 of 179
- Oncology 53.1k
- Cancer Research 7.6k
- Pulmonary and Respiratory Medicine 15.6k
- Molecular Biology 19.4k
- Immunology 4.4k
Countries citing papers authored by James Larkin
This map shows the geographic impact of James Larkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Larkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Larkin more than expected).
Fields of papers citing papers by James Larkin
This network shows the impact of papers produced by James Larkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Larkin. The network helps show where James Larkin may publish in the future.
Co-authors
The 25 scholars most cited alongside James Larkin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 562 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma Hit paper breakdown → | 2015 | 6953 |
| 2 | Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation Hit paper breakdown → | 2011 | 6392 |
| 3 | Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing Hit paper breakdown → | 2012 | 6392 |
| 4 | Pembrolizumab versus Ipilimumab in Advanced Melanoma Hit paper breakdown → | 2015 | 4911 |
| 5 | Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2015 | 4852 |
| 6 | Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma Hit paper breakdown → | 2017 | 4618 |
| 7 | Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma Hit paper breakdown → | 2019 | 2885 |
| 8 | Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial Hit paper breakdown → | 2015 | 2303 |
| 9 | Renal cell carcinoma Hit paper breakdown → | 2017 | 2049 |
| 10 | Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2019 | 2001 |
| 11 | Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2017 | 1963 |
| 12 | Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma Hit paper breakdown → | 2012 | 1821 |
| 13 | Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma Hit paper breakdown → | 2017 | 1792 |
| 14 | Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma Hit paper breakdown → | 2014 | 1710 |
| 15 | Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma Hit paper breakdown → | 2014 | 1559 |
| 16 | Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma Hit paper breakdown → | 2018 | 1513 |
| 17 | Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group Hit paper breakdown → | 2012 | 1224 |
| 18 | Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial Hit paper breakdown → | 2018 | 1161 |
| 19 | Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma Hit paper breakdown → | 2017 | 1150 |
| 20 | Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial Hit paper breakdown → | 2015 | 1137 |
About James Larkin
James Larkin is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Cancer Research and Dermatology, having authored 562 papers that have together received 99.2k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (213 papers), Renal cell carcinoma treatment (149 papers), Melanoma and MAPK Pathways (103 papers), Cutaneous Melanoma Detection and Management (62 papers), Cancer Genomics and Diagnostics (27 papers), Brain Metastases and Treatment (10 papers), CAR-T cell therapy research (9 papers) and Genetic Associations and Epidemiology (9 papers). The work is most often cited by research in Oncology (53.1k citations), Cancer Research (7.6k citations), Pulmonary and Respiratory Medicine (15.6k citations), Molecular Biology (19.4k citations) and Immunology (4.4k citations). James Larkin has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Caroline Robert, Georgina Venetia Long, Martin Eric Gore, Lavinia Anne Spain, Charles Swanton, Matteo Salvatore Carlino, John B.A.G. Haanen, Solange Peters, Karin Jordan and Franck Carbonnel. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, The Lancet Oncology, Journal of Clinical Oncology and New England Journal of Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.